Axogen, Inc. Common Stock
AXGNAxogen, Inc. is a biotechnology company focused on the development and commercialization of surgical grafts to repair, replace, or regenerate peripheral nerve tissue. The company specializes in products aimed at nerve repair and regeneration, providing solutions for nerve injuries resulting from surgery, trauma, and other conditions. Based in Florida, Axogen aims to improve functional outcomes for patients with nerve damage.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| February 12, 2010 | $1.00 | 2010-01-27 | 2010-01-29 |
| March 11, 2005 | $0.06 | 2005-02-23 | 2005-02-25 |
Dividends Summary
- Axogen, Inc. Common Stock has issued 2 dividend payments over the past 5 years
- The most recent dividend was paid 5778 days ago, on February 12, 2010
- The highest dividend payed out to investors during this period was $1.00 per share
- The average dividend paid during this period was $0.53 per share.
Company News
Axogen received FDA Biologics License Application approval for AVANCE, an acellular nerve scaffold for treating peripheral nerve discontinuities in patients aged 1 month and older, with commercial availability expected in early Q2 2026.
The Schall Law Firm is investigating potential securities law violations by Axogen, Inc. after the company's stock dropped over 9% following an FDA application extension announcement for its Avance® Nerve Graft.
DexCom, Inc. is scheduled to release its second-quarter 2024 results on July 25. The company's revenues are expected to grow 19% year-over-year, driven by increased product volume and global awareness of its continuous glucose monitoring system. However, rising costs and competition may have weighed on its performance.
AXGN earnings call for the period ending September 30, 2021.
